Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy

Iparomlimab and Tuvonralimab Injection (QL1706) is a bifunctional combination antibody targeting both programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4). This is a prospective clinical study that plans to enroll screened, eligible early-stage breast-cancer patients to receive neoadjuvant QL1706 plus chemotherapy (four cycles of TP ± four cycles of AC). After the four TP cycles, imaging and core biopsy will be performed. Patients who achieve radiologic complete response will proceed directly to surgery; those who do not will receive four additional AC cycles be

Trial Details

NCT ID
NCT07372079
Phase
PHASE2
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • QL1706 combined with Chemotherapy
Locations (sample)
  • Tianjin, China|39.14222,117.17667

Key Eligibility Criteria

  • Voluntarily join this study, sign the informed consent form, and demonstrate good compliance;
  • Age: 18-75 years old (at the time of signing the informed consent form);
  • ECOG PS score: 0-1; expected survival time exceeding 6 months;
  • Patients with primary breast cancer confirmed by histopathological or cytological examination;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →